Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

Weight Watchers is Novo Nordisk's latest partnersip.

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...

Retail chatter around WW International surged Tuesday after the company’s expanded collaboration with Novo Nordisk officially ...